IMMUNOVANT, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $18.26 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-06-30 was $18.26, a 11.34% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-06-30 was $16.40, a 4.15% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-06-30 was $17.11, a 0.06% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-06-30 was $17.12, a 151.76% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2026 was $16.68, a 12.47% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $14.83, a 24.00% increase from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $11.96, a 80.39% increase from fiscal 2023.
- IMMUNOVANT, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $6.63, a 71.14% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.26 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $16.68 10-K · filed 2026-05-20 | |||
| 2025-12-31 | $16.55 10-Q · filed 2026-02-06 | |||
| 2025-09-30 | $16.64 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $16.40 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $14.83 10-K · filed 2025-05-29 | |||
| 2024-12-31 | $14.43 10-Q · filed 2025-02-06 | |||
| 2024-09-30 | $14.61 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $17.11 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $11.96 10-K · filed 2024-05-29 | |||
| 2023-12-31 | $9.24 10-Q · filed 2024-02-12 | |||
| 2023-09-30 | $9.85 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $17.12 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $6.63 10-K · filed 2023-05-22 | |||
| 2022-12-31 | $6.31 10-Q · filed 2023-02-03 | |||
| 2022-09-30 | $7.09 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $6.80 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $22.97 10-K · filed 2022-06-08 | |||
| 2021-12-31 | $23.45 10-Q · filed 2022-02-04 | |||
| 2021-09-30 | $23.68 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $27.10 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $17.14 10-K · filed 2021-06-01 | |||
| 2020-12-31 | $16.94 10-Q · filed 2021-02-16 | |||
| 2020-09-30 | $14.86 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $8.43 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $7.23 10-K · filed 2020-06-29 | |||
| 2019-12-31 | $7.13 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |